Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
Teresa A SimonLixian DongSamy SuissaKaleb MichaudSofia PedroMarc HochbergMaarten BoersJohan AsklingThomas FrisellAnja StrangfeldYvette MeißnerVadim KhaychukAlyssa DominiqueMichael A MaldonadoPublished in: Annals of the rheumatic diseases (2023)
Consistent with the warnings and precautions of the abatacept label, this analysis suggests a potential increase in NMSC risk with abatacept use compared with csDMARDs. No significant increase was observed compared with b/tsDMARDs, but the lower limit of the 95% CI was close to unity.